Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
Several public health officials endorse using a federal law to slash hepatitis C drug prices in Louisiana and avoid drug bills that could cripple the state budget.
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
The drugs, approved by the FDA for children earlier this month, can run $100,000 for a course of treatment.
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.